Entropy Technologies LP Reduces Holdings in Stryker Corporation $SYK

Entropy Technologies LP trimmed its position in Stryker Corporation (NYSE:SYK) by 53.8% during the 1st quarter, Holdings Channel.com reports. The fund owned 19,405 shares of the medical technology company’s stock after selling 22,600 shares during the period. Entropy Technologies LP’s holdings in Stryker were worth $6,376,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. VanderPol Investments L.L.C. increased its holdings in shares of Stryker by 1.4% in the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock valued at $732,000 after purchasing an additional 28 shares during the period. KCM Investment Advisors LLC raised its holdings in shares of Stryker by 1.5% during the fourth quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock worth $653,000 after purchasing an additional 28 shares during the last quarter. Rossby Financial LCC lifted its position in Stryker by 6.6% during the fourth quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock valued at $159,000 after purchasing an additional 28 shares during the period. Tcfg Wealth Management LLC boosted its holdings in Stryker by 2.7% in the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock valued at $403,000 after purchasing an additional 29 shares during the last quarter. Finally, Mechanics Financial Corp grew its position in Stryker by 1.2% during the 4th quarter. Mechanics Financial Corp now owns 2,458 shares of the medical technology company’s stock worth $864,000 after purchasing an additional 30 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Trading Up 3.7%

Shares of Stryker stock opened at $330.69 on Friday. The firm has a 50-day simple moving average of $314.69 and a two-hundred day simple moving average of $335.66. The company has a market cap of $126.77 billion, a P/E ratio of 38.27, a price-to-earnings-growth ratio of 2.04 and a beta of 0.77. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.14. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. During the same quarter last year, the business earned $2.84 earnings per share. Stryker’s revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities analysts predict that Stryker Corporation will post 14.99 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s payout ratio is presently 40.74%.

Insiders Place Their Bets

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of the stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the transaction, the vice president directly owned 13,137 shares of the company’s stock, valued at $3,728,937.45. This trade represents a 28.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 323,264 shares of company stock worth $100,659,489. Company insiders own 4.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on SYK. Robert W. Baird set a $385.00 price objective on Stryker in a research note on Friday, May 1st. Wall Street Zen lowered Stryker from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Barclays reduced their price target on Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research report on Monday, May 4th. JPMorgan Chase & Co. decreased their price target on Stryker from $445.00 to $400.00 and set an “overweight” rating for the company in a report on Friday, May 1st. Finally, The Goldman Sachs Group restated a “neutral” rating and issued a $361.00 price objective on shares of Stryker in a research report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $392.52.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.